SCHEMBL700466

SCHEMBL700466

NCCOS(=O)(=O)OCCN

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 12/20 0.36
CA2 P00918 12/20 0.36
CA9 Q16790 8/20 0.36
CA12 O43570 2/20 0.35
CA3 P07451 2/20 0.35
CA4 P22748 2/20 0.35
CA6 P23280 2/20 0.35
CA5A P35218 2/20 0.35
CA7 P43166 2/20 0.35
CA14 Q9ULX7 2/20 0.35
CA5B Q9Y2D0 2/20 0.35
LMNA P02545 2/20 0.32
SLC6A6 P31641 1/20 0.32
CYP2C19 P33261 1/20 0.32
BLM P54132 1/20 0.32
KDM4E B2RXH2 1/20 0.30
USP2 O75604 1/20 0.30
ALDH1A1 P00352 1/20 0.30
MMP9 P14780 1/20 0.30
ALOX15 P16050 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6014638 0.87 CA1 (0.46) CA1CA2CA9CA12CA3
SCHEMBL27897320 0.83
SCHEMBL8506764 0.81 CA1 (0.46) CA1CA2CA9CA12CA3
Ammonia Solution, Strong SCHEMBL27943704 0.81 USP2 (0.36) CA1CA2USP2TSHR
SCHEMBL1856656 0.80 CA1 (0.36) CA1CA2CA9CA12CA3
SCHEMBL700982 0.79 CA1 (0.50) CA1CA2CA9CA12CA3
SCHEMBL1176428 0.79 CA1 (0.61) CA1CA2CA9CA12CA3
SCHEMBL27632893 0.79 LMNA (0.35) LMNASLC6A6CYP2C19BLM
SCHEMBL2173072 0.78 CA1 (0.59) CA1CA2CA9CA12CA3
SCHEMBL7512081 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059128-A1 PROCESSES AND CATAYLST SYSTEMS FOR PRODUCING MONOETHANOLAMINE FROM GLYCOLALDEHYDE ARCHER DANIELS MIDLAND CO (US) 2025-02-20 US claimed
US-12162817-B2 Processes and catalyst systems for producing monoethanolamine from glycolaldehyde ARCHER-DANIELS-MIDLAND COMPANY (US) 2024-12-10 US claimed
CN-112601733-B Method and catalyst system for producing monoethanolamine from glycolaldehyde 阿彻丹尼尔斯米德兰德公司 2023-10-27 CN claimed
CN-114989111-B Synthetic method for preparing 2-mercaptothiazoline 广州市三珍商贸有限公司 2023-03-28 CN claimed
CN-114989111-A Synthetic method for preparing 2-mercaptothiazoline 广州市三珍商贸有限公司 2022-09-02 CN claimed
US-20210309604-A1 PROCESSES AND CATAYLST SYSTEMS FOR PRODUCING MONOETHANOLAMINE FROM GLYCOLALDEHYDE ARCHER DANIELS MIDLAND COMPANY (US) 2021-10-07 US claimed
EP-3830071-A1 PROCESSES AND CATAYLST SYSTEMS FOR PRODUCING MONOETHANOLAMINE FROM GLYCOLALDEHYDE Archer Daniels Midland Company (US) 2021-06-09 EP claimed
CN-107722953-B Preparation method of branched polyethyleneimine and shale intercalation inhibitor 西南石油大学 2020-02-11 CN claimed
WO-2020028322-A1 PROCESSES AND CATAYLST SYSTEMS FOR PRODUCING MONOETHANOLAMINE FROM GLYCOLALDEHYDE ARCHER DANIELS MIDLAND COMPANY (US) 2020-02-06 WO claimed
CN-105152985-B Monoethanolamine produces the cyclic process of taurine 胡松洲 2018-03-27 CN claimed
EP-2699626-A1 CHEMICALLY MODIFIED CELLULOSE FIBROUS MESHES FOR USE AS TISSUE ENGINEERING SCAFFOLDS University of Massachusetts Medical School (US) 2014-02-26 EP claimed
WO-2012141938-A1 CHEMICALLY MODIFIED CELLULOSE FIBROUS MESHES FOR USE AS TISSUE ENGINEERING SCAFFOLDS UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) 2012-10-18 WO claimed
EP-1064013-A4 $i(IN VITRO) FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES UNIV WASHINGTON (US) 2005-05-11 EP claimed
EP-1064013-A1 $i(IN VITRO) FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES University of Washington (US) 2001-01-03 EP claimed
WO-1999045947-A9 IN VITRO FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES UNIV WASHINGTON (US) 2000-03-02 WO claimed
WO-1999045947-A1 IN VITRO FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES UNIVERSITY OF WASHINGTON (US) 1999-09-16 WO claimed
US-5643562-A ANTIDEPOSIT AGENTS FOR PROTEINS FOR MEDICAL DIAGNOSIS OF DISEASES QUEEN'S UNIVERSITY OF KINGSTON (CA) 1997-07-01 US claimed
CN-1043158-A Amino-functional compounds as builders/dispersants in detergent compositions PROCTER & GAMBLE (US) 1990-06-20 CN claimed
US-4618716-A AND AMMONIA OR ETHYLENE POLYAMINE AIR PRODUCTS AND CHEMICALS, INC. (US) 1986-10-21 US claimed
US-4324724-A Manufacture of polyalkylenepolyamines BASF AKTIENGESELLSCHAFT (DE) 1982-04-13 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12162817-B2 Processes and catalyst systems for producing monoethanolamine from glycolaldehyde NAAA, PNMT, GMDS CA1 480/4885CA2 1825/4885CA9 464/4885
US-20250059128-A1 PROCESSES AND CATAYLST SYSTEMS FOR PRODUCING MONOETHANOLAMINE FROM GLYCOLALDEHYDE DLST, CEPT1, AADAT CA1 445/4885CA2 1009/4885CA9 726/4885
US-20210309604-A1 PROCESSES AND CATAYLST SYSTEMS FOR PRODUCING MONOETHANOLAMINE FROM GLYCOLALDEHYDE DLST, CEPT1, AADAT CA1 445/4885CA2 1009/4885CA9 726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.